{'fraction_non_alphanumeric': 0.023157894736842106, 'fraction_numerical': 0.018947368421052633, 'mean_word_length': 5.704225352112676, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CYP3A4 gene polymorphism is correlated with individual consumption of sufentanil

Pain is one of the major adverse clinical outcomes of cesarean section (CS). In the past few years, researchers and physicians have been optimizing post‐operative analgesic modalities, but the results are still undesirable for the parturient. The cytochrome P‐450 3A4 (CYP3A4) gene has been reported to contribute significantly to human liver microsomal oxidation of sufentanil and alfentanil.